Malignancy‐induced autoimmunity to MUC1: initial antibody characterization
Authors:
- 4 December 2005
- journal article
- Published by Wiley in Chemical Biology & Drug Design
- Vol. 66 (6) , 357-363
Abstract
Numerous reports document the existence of autoantibodies to MUC1 in the circulation of individuals with breast and other solid malignancies, with the majority of researchers utilizing MUC1 peptides in their detection. This report documents the purification, using peptide and whole molecule, and characterization of such autoantibodies from an individual with an unusual, highly MUC1-positive, myosarcoma. Purification of autoantibodies from serum was performed using affinity chromatography against either MUC1 peptide or whole molecule MUC1 [derived both from the patient (Pt-MUC1) and from a pool of sera from patients with advanced breast cancer (ABC-MUC1)]. Enzyme-linked immunosorbent assays (ELISAs) were used to compare specificity of purified autoantibodies. Peptide epitopes were determined by Ptifcan system against 7-mer peptides covering the 20 amino acid repeat of the MUC1 extracellular domain. Substantially higher amounts of autoantibodies were isolated when purifying against Pt-MUC1 rather than either ABC-MUC1 or peptide. Whole molecule purified autoantibodies demonstrated an increased specificity for tumour-derived MUC1. Pt-MUC1 autoantibodies were of both the immunoglobulin (Ig)G and IgM class, whilst autoantibodies purified against ABC-MUC1 and MUC1 peptide were IgG only. A greater range of peptide epitopes was defined by those autoantibodies purified against whole molecule. This report presents data indicating the presence of autoantibodies to MUC1 in an individual diagnosed with a MUC1 over-expressing myosarcoma. Confirmation of these autoantibodies as being specific for tumour-associated MUC1 is given. Further, it suggests that, although autoantibodies are present that recognize core protein determinants, the initial, and dominant, immunizing epitope is not purely pretentious in nature.Keywords
This publication has 24 references indexed in Scilit:
- Binding patterns of DTR-specific antibodies reveal a glycosylation-conditioned tumor-specific epitope of the epithelial mucin (MUC1)Glycobiology, 2004
- Designer Glycopeptides for Cytotoxic T Cell–based Elimination of CarcinomasJournal of Experimental Medicine, 2004
- Effect of Glycosylation on MUC1 Humoral Immune Recognition: NMR Studies of MUC1 Glycopeptide−Antibody InteractionsBiochemistry, 2002
- Antibody-dependent cell-mediated cytotoxicity can be induced by MUC1 peptide vaccination of breast cancer patientsInternational Journal of Cancer, 2001
- Effect of immunological adjuvant combinations on the antibody and T-cell response to vaccination with MUC1–KLH and GD3–KLH conjugatesVaccine, 2000
- MUC1 and cancerBiochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, 1999
- The objective measurement of remission and progression in metastatic breast cancer by use of serum tumour markersEuropean Journal of Cancer, 1999
- Summary Report on the ISOBM TD-4 Workshop: Analysis of 56 Monoclonal Antibodies against the MUC1 MucinTumor Biology, 1998
- Human antibodies against the polymorphic epithelial mucin in ovarian cancer patients recognise a novel sequence in the tandem repeat regionEuropean Journal of Cancer, 1996
- A new antigen on the epithelial membrane: its immunoperoxidase localisation in normal and neoplastic tissue.Journal of Clinical Pathology, 1979